Get started
Author

Natalia Maćkowska‐Maślak

Observed names: Maćkowska-Maślak, Natalia, N. Maćkowska-Maślak, Natalia Maćkowska, Natalia Maćkowska-Maślak
ORCID: 0000-0002-0296-4597
Observed ORCID: 0000-0002-0296-4597
OpenAlex ID: A5034716995
CRISPRi for specific inhibition of miRNA clusters and miRNAs with high sequence homology
2022 · Monika Drobna-Śledzińska, Natalia Maćkowska-Maślak, et al. · Scientific Reports · 31
PDF
DNA Methylation in T-Cell Acute Lymphoblastic Leukemia: In Search for Clinical and Biological Meaning
2021 · Natalia Maćkowska, Monika Drobna-Śledzińska, et al. · International Journal of Molecular Sciences · 21
PDF
Small RNA-Seq Reveals Similar miRNA Transcriptome in Children and Young Adults with T-ALL and Indicates miR-143-3p as Novel Candidate Tumor Suppressor in This Leukemia
2022 · Małgorzata Dawidowska, Natalia Maćkowska-Maślak, et al. · International Journal of Molecular Sciences · 7
PDF
Pre-Clinical Evaluation of the Hypomethylating Agent Decitabine for the Treatment of T-Cell Lymphoblastic Lymphoma
2023 · Lien Provez, Tom Putteman, et al. · Cancers · 6
PDF
Multiomics to investigate the mechanisms contributing to repression of PTPRC and SOCS2 in pediatric T‐ALL: Focus on miR‐363‐3p and promoter methylation
2022 · Monika Drobna‐Śledzińska, Natalia Maćkowska‐Maślak, et al. · Genes Chromosomes and Cancer · 4
PDF
P332: Mir-625-5p Is Novel Candidate Oncomir in T-cell Acute Lymphoblastic Leukemia Implicated in Regulation of Apoptosis Via Repression of Harakiri
2022 · N. Maćkowska-Maślak, M. Drobna-Śledzińska, et al. · HemaSphere · 1
KSR2 is a novel oncogene in TAL1 subtype of T-cell acute lymphoblastic leukemia with potential clinical and prognostic implications
2026 · Monika Drobna-Śledzińska, Natalia Maćkowska-Maślak, et al. · Haematologica
PDF
KSR2 is a novel oncogene in TAL1 subtype of T-cell acute lymphoblastic leukemia with potential clinical and prognostic implications - Supplementary Methods
2026 · Drobna-Śledzińska, Monika, Maćkowska-Maślak, Natalia, et al. · Zenodo (CERN European Organization for Nuclear Research)
KSR2 is a novel oncogene in TAL1 subtype of T-cell acute lymphoblastic leukemia with potential clinical and prognostic implications - Raw experimental data pt. 2
2026 · Drobna-Śledzińska, Monika, Maćkowska-Maślak, Natalia, et al. · Zenodo (CERN European Organization for Nuclear Research)
KSR2 is a novel oncogene in TAL1 subtype of T-cell acute lymphoblastic leukemia with potential clinical and prognostic implications - Raw experimental data pt. 1
2026 · Drobna-Śledzińska, Monika, Maćkowska-Maślak, Natalia, et al. · Zenodo (CERN European Organization for Nuclear Research)
Functional anaysis of miR-143-3p/KSR2 interaction and oncogenic function in JURKAT and ALL-SIL T-cell acute lymphoblastic leukemia cell lines
2023 · Maćkowska-Maślak, Natalia, Drobna-Śledzińska, Monika, et al. · Zenodo (CERN European Organization for Nuclear Research)
KSR inhibitor APS-2-79 sensitivity test in JURKAT and ALL-SIL T-cell acute lymphoblastic leukemia cell lines measured by Cell Counting Kit 8
2023 · Drobna-Śledzińska, Monika, Dawidowska, Małgorzata, et al. · Zenodo (CERN European Organization for Nuclear Research)
P340: in Search for Genomic and Transcriptomic Predictors of Relapse in Pediatric T-all
2023 · Małgorzata Dawidowska, Roman Jaksik, et al. · HemaSphere
Rola układu immunologicznego w patogenezie oraz progresji płaskonabłonkowego raka głowy i szyi
2019 · Natalia Maćkowska, Agnieszka Sobecka, et al. · Letters in Oncology Science
PDF
Works count: 14
Citation count: 70
H-index: 4
I10-index: 2
Year
Topic
Type